388 results on '"Vanderkerken, K"'
Search Results
2. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
3. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
4. PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
5. P860: THE DE NOVO DNA METHYLTRANSFERASE DNMT3B PLAYS AN IMPORTANT ROLE IN MM CELL GROWTH, CLONOGENICITY AND DRUG RESPONSE
6. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
7. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
8. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
9. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway
10. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow
11. Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model
12. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation
13. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models
14. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells
15. Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients
16. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model
17. Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance
18. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor
19. Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour
20. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138 + MM-cell proliferation
21. Evaluation of a novel class of sulfonanilides for targeted treatment of multiple myeloma: Dual-mechanism compounds inhibiting HIF1α-signaling and inducing apoptosis: V109
22. Tumour-promoting properties of mesenchymal stem cells in multiple myeloma: a potential risk for therapeutical use after haematopoietic stem cell transplantation in myeloma patients?: P878
23. Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease: 30
24. Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma: 14
25. The Effect of JNJ-26481585 in Murine Myeloma Models: B144
26. The European Myeloma Stem Cell Network (MSCNET): B552
27. Probing the Stem Cell in the 5T33 Multiple Myeloma Model: B216
28. BMSC-induced Drug Resistance by Arresting MM Cells at First Contact: B145
29. PS1369 AMITRIPTYLINE STRENGTHENS THE EFFECTS OF BORTEZOMIB AND MELPHALAN TREATMENT IN MULTIPLE MYELOMA BY INHIBITING ACID SPHINGOMYELINASE
30. PF577 TARGETING PROTEIN ARGININE METHYLTRANFERASE PRMT5 IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?
31. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
32. Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma
33. Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
34. 5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
35. Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
36. Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma
37. RPL5 on 1p22 is recurrently deleted in multiple myeloma and its expression is linked to Bortezomib response
38. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
39. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
40. The myeloma stem cell concept, revisited: from phenomenology to operational terms
41. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study
42. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
43. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib
44. Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease
45. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
46. Osteoprotegerin and the development of myeloma bone disease
47. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
48. APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo
49. Zoledronic acid prevents the development of myeloma bone disease and increases survival
50. Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.